Biogen, Eisai sink as much-awaited Alzheimer’s results raise more questions

The drug, dubbed BAN2401, slowed declines associated with Alzheimer’s disease by 30 percent at its highest dose in the trial, compared with placebo, after 18 months.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.